3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Paclitaxel
71
Bevacizumab
64
Carboplatin
56
pembrolizumab
46
olaparib
32
Gemcitabine
29
Specimen Handling
27
Cyclophosphamide
26
liposomal doxorubicin
24
Magnetic Resonance Spectroscopy
24
Cisplatin
22
niraparib
21
Taxes
19
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
13
Disulfides
13
Fulvestrant
12
Blood Specimen Collection
11
durvalumab
10
Oxaliplatin
10
mirvetuximab soravtansine
9
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Interleukin-15
×
1 year
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled